Back to results
US 10,851,115 B2Granted
Heterocyclic compounds as RSV inhibitors
AssigneeEnanta Pharmaceuticals, Inc.
InventorsIn Jong Kim, Joseph Panarese, Thomas P. Blaisdell, Jianming Yu, Brian C. Shook, Yat Sun Or
Life of this patent
Estimating the term…
Abstract
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Claims23
A compound represented by Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- {circle around (A)} is selected from the group consisting of:
- 1) optionally substituted aryl;
- 2) optionally substituted heteroaryl;
- 3) optionally substituted —C3-C12 cycloalkenyl;
- 4) optionally substituted 3- to 12-membered heterocycloalkyl;
- 5) optionally substituted arylalkyl;
- 6) optionally substituted heteroarylalkyl;
- 7) optionally substituted-C3-C12 cycloalkyl-C1-C6 alkyl;
- 8) optionally substituted-C3-C12 cycloalkenyl-C1-C6 alkyl;
- and
- 9) optionally substituted 3- to 12-membered heterocycloalkyl-C1-C6 alkyl;
- {circle around (B)} is selected from the groups below;
- {circle around (C)} is aryl or heteroaryl;
- L is absent, —CONH—, or —NHCO—;
- One of X and Y is selected from O, S, and NR4, and the other is N or CR5;
- Each R1 and R2 is independently selected from the group consisting of:
- halogen, cyano, nitro, hydroxyl, protected hydroxyl, amino, protected amino, optionally substituted —C1-C8 alkyl, and optionally substituted —C1-C8 alkoxy;
- Each R3 is independently selected from the group consisting of:
- 1) halogen;
- 2) optionally substituted —C1-C8 alkoxy;
- 3) optionally substituted —C1-C8 alkyl;
- 4) optionally substituted —C2-C8 alkenyl;
- 5) optionally substituted —C2-C8 alkynyl;
- 6) optionally substituted —C3-C12 cycloalkyl;
- 7) optionally substituted —C3-C12 cycloalkenyl;
- 8) optionally substituted 3- to 12-membered heterocycloalkyl;
- 9) optionally substituted aryl;
- 10) optionally substituted heteroaryl;
- 11) optionally substituted arylalkyl;
- 12) optionally substituted aryloxy;
- 13) —C(O)R12;
- 14) —C(O)NR13R14;
- 15) —C(O)NR11S(O)2R12;
- 16) —S(O)2NR13R14;
- 17) —NR13R14;
- 18) —NR11S(O)2R12;
- 19) —NR11C(O)R12;
- 20) —NR11C(O)NR13R14;
- and
- 21) —NR11C(O)NHS(O)2R12,
- n is 0, 1, 2, 3 or 4;
- m is 0, 1, 2, 3 or 4;
- v is 0, 1, 2, or 3;
- R4 is hydrogen or optionally substituted —C1-C8 alkyl;
- R5 is hydrogen, halogen, optionally substituted —C1-C8 alkyl, or optionally substituted —C1-C8 alkoxy;
- R12 at each occurrence is independently selected from the group consisting of:
- 1) Hydrogen;
- 2) Halogen;
- 3) Hydroxyl;
- 4) optionally substituted —C1-C8 alkoxy;
- 5) optionally substituted —C1-C8 alkyl;
- 6) optionally substituted —C2-C8 alkenyl;
- 7) optionally substituted —C2-C8 alkynyl;
- 8) optionally substituted —C3-C8 cycloalkyl;
- 9) optionally substituted —C3-C8 cycloalkenyl;
- 10) optionally substituted 3- to 8-membered heterocycloalkyl;
- 11) optionally substituted aryl;
- 12) optionally substituted arylalkyl;
- 13) optionally substituted heteroaryl;
- and
- 14) optionally substituted heteroarylalkyl;
- R11, R13 and R14 are each independently selected from hydrogen, optionally substituted —C1-C8-alkyl, optionally substituted —C2-C8-alkenyl, optionally substituted —C2-C8-alkynyl;
- optionally substituted —C3-C8-cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl;
- alternatively R13 and R14 are taken together with the nitrogen atom they attached to form a heterocyclic ring.
62 more elements
A compound selected from the compounds set forth below or a pharmaceutically acceptable salt thereof:
- Com-
- pound
- Structure
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
168 more elements
Dependencies are inferred from the claim text.